Incidence of Type 2 Diabetes With Verapamil Compared With Other Calcium Channel Blockers
Main finding · T2D incidenceResult — go to the resultIncidence rate ratio 0.77 95% CI 0.63–0.94Authors' conclusion
Verapamil use is associated with a lower incidence of type 2 diabetes compared with other CCBs.
Study context
- Population
- Random sample of Australians in national subsidized health care databases who initiated calcium channel blocker (CCB) treatment (at least two supplies), July 2003–December 2014
- Participants
- 90,026 participants
- Exposure
- Verapamil vs other CCBs
- Verapamiln = 4,485
- Other CCBsn = 85,541reference
- Outcome
- Incident T2D (subsequent glucose-lowering treatment or National Diabetes Services Scheme registration), with death as competing event
- Follow-up
- median 1.6-year follow-up
Methodological detailsmultivariable propensity score adjustment, multistate Poisson regression
- Multivariable propensity score adjustment
- Multistate Poisson regression
Main finding
T2D incidence
Incidence rate ratio
0.77
95% CI 0.63–0.94
Events by group
Verapamil
8.8 per 1,000 person-years
101 of 4,485
Other CCBs
11.4 per 1,000 person-years
2,622 of 85,541
Verapamilvs Other CCBs
IRR 0.77 (95% CI 0.63–0.94)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | Verapamil | Other CCBs | Absolute risk difference (95% CI) | |
|---|---|---|---|---|
| Probability of T2D, typical clinical profile · 6 years | 4.2% (CI 3.3–5.3) | 5.4% (CI 4.7–6.3) | 1.3% (−0.1-2.4) | |
| −10123Difference (linear scale) |
Sensitivity analyses
- Results were robust across multiple sensitivity analyses
Original publication
Incidence of Type 2 Diabetes With Verapamil Compared With Other Calcium Channel Blockers. Diabetes Care. Published 30 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →